Functional Assay Panels
ChemPartner delivers integrated small molecule CMC services that support drug candidates from early development through IND, NDA, and commercialization. Our coordinated platform combines API development and manufacturing, formulation development, analytical characterization, solid-state R&D, process optimization, pilot-scale production, large-scale manufacturing, and quality management within a unified development strategy.
Pre-configured functional assay panels for rapid compound profiling. Run a candidate set across a defined panel and get comparable potency, selectivity and phenotype data in one dataset, rather than assembling results from assays run months and methods apart.
概述
赞助商在评估生物制剂CMC外包合作伙伴时需要了解的一切——从产能到合规性。
| ID | Assay Type | Cell Type |
| 1 | Mixed Lymphocyte Reaction (MLR) | Primary human/mouse DC + T cells |
| 2 | CMV antigen recall | Primary human T cells |
| 3 | T cell activation (anti-CD3/CD28) | Primary human/mouse T cells |
| 4 | T cell activation (SEB super-antigen) | Primary human T cells |
| 5 | T cell and tumor cell co-culture | Primary human T cells + engineered tumor cells |
| 6 | OT-I T cell and OVA tumor cell co-culture | T cells from OT-I mice + OVA-expressing tumor cells |
| 7 | Treg suppressive assay | Primary mouse T cells |
| 8 | Treg differentiation | Primary human/mouse T cells |
| 9 | Th1 differentiation | Primary human/mouse T cells |
| 10 | Th2 differentiation | Primary human/mouse T cells |
| 11 | Th17 differentiation | Primary human/mouse T cells |
| 12 | M1/M2 Macrophage differentiation | Primary human/mouse macrophages |
| 13 | Macrophage phagocytosis | Primary human/mouse macrophages |
| 14 | Mouse T cell and M2 Macrophage co-culture | Mouse T cells + M2 Macrophages |
| 15 | NLRP3 activation assay | Mouse BMDM, human THP-1 cells |
| 16 | Basophil activation assay | Human whole blood |
| 17 | B cell activation and proliferation | Primary human/mouse B cells or whole blood |
| 18 | Target specific reporter gene assay (41BB, etc.) | Engineered cell lines |
| 19 | Antibody-Dependent Cellular Cytotoxicity (ADCC) | Primary human NK or NK-92-CD16 + target cells |
| 20 | NK cell cytotoxicity | Primary human NK or NK-92-CD16 + target cells |
| 21 | Complement Dependent Cytotoxicity (CDC) | Complement + target cells |
| 22 | ELISpot | Primary human PBMCs or mouse T cells or splenocytes or TILs Treated with anti-CD3 or peptides or peptide loaded APC or target cells |
